Search Results for “AstraZeneca” – Page 29 – media

FDA approves new treatment for adults with mantle cell lymphoma

The U.S. Food and Drug(FDA) Administration today granted accelerated approval to Calquence (acalabrutinib) for the treatment of adults with mantle cell lymphoma who have received at least one prior therapy.
- Source: Prnewswire
- 785
- November 1, 2017
Calquence FDA mantle cell lymphoma New Approvals
Merck sales slip, even as Keytruda gains ground

Keytruda (pembrolizumab) was the main bright spot for Merck as it weathered blows from the NotPetya cyber attack, new competition and pricing pressures in hepatitis C.
- Source: 4-traders
- 692
- October 31, 2017
hepatitis inhibitor keytruda Market Views Opdivo
FDA Approves Once-Weekly Bydureon BCise (exenatide) for Patients with Type-2 Diabetes

AstraZeneca today announced that the US Food and Drug Administration (FDA) has approved Bydureon® BCise™ (exenatide extended-release) injectable suspension, a new formulation of Bydureon (exenatide extended-release) injectable suspension in an improved once-weekly, single-dose autoinjector device for adults with type-2 diabetes whose blood sugar remains uncontrolled on one or more oral medicines in addition to diet and exercise, to improve glycemic control.
- Source: AstraZeneca
- 461
- October 25, 2017
Bydureon diabetes New Approvals
China’s Cardiovascular Drugs Import and Export Report

Cardiovascular drugs are medicines used to treat medical conditions associated with the heart or the circulatory system (blood vessels), such as arrhythmias, blood clots, coronary artery disease, high or low blood pressure, high cholesterol, heart failure, and strokes, whose therapeutic effects aim to improve cardiac functions, regulate blood flow of heart and change the circulatory system of blood distribution among other things.
- Source: Ddu
- 1,547
- October 19, 2017
cardiovascular Market Reports
Big Pharma Gets Boost as China Speeds Up New Drug Approvals

For decades, Chinese patients have struggled to gain access to cutting-edge medicines thanks to bureaucratic delays that have hamstrung drug development. Now a sweeping government overhaul of drug approvals is poised to change that.
- Source: bloomberg
- 512
- October 10, 2017
Chinese drug approval Market Views
Merck launches frontline PhIII lung cancer study for Keytruda/Yervoy combo

Merck took a dominant position in frontline lung cancer with the approval of a combination of Keytruda and chemo. And it isn’t just waiting around to see if any combination of a PD-(L)1 with a CTLA4 can come along and knock it off its market-leading perch.
- Source: Endpts
- 615
- October 9, 2017
cancer Clinical Trials lung Phase
Boehringer’s new risk-prediction model will tap patients who could be good Jardiance candidates

Boehringer Ingelheim has reason to believe its diabetes medication Jardiance can help fend off cardiovascular death, kidney failure and hospitalization for heart failure. And now, it’s developing a model to help predict which patients are best suited for treatment with the therapy.
- Source: company insights
- 558
- September 28, 2017
cardiovascular Company Insight diabetes kidney
FDA approves Adherium’s new inhaler monitoring device

The US Food and Drug Administration (FDA) has cleared Adherium for its new inhaler monitoring device for AstraZeneca’s Symbicort aerosol inhaler.
- Source: medicaldevices-business-review
- 578
- September 5, 2017
Company Insight FDA inhaler respiratory
AZ, Merck link to develop and commercialise cancer drugs

AstraZeneca and Merck & Co have announced a global strategic oncology collaboration to co-develop and co-commercialise the former’s Lynparza and selumetinib for multiple cancer types.
- Source: pharmatimes
- 494
- July 31, 2017
cancer Lynparza Market Views Researches therapy
EU OKs first-line use of AZ’ Faslodex

EU regulators are permitting the use of AstraZeneca’s breast cancer drug Faslodex at an earlier stage of the treatment pathway in patients with certain forms of the disease.
- Source: pharmatimes
- 765
- July 28, 2017
breast cancer EU inhibitor New Approvals

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.